NCT04633122 2026-04-03
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
Clinical Trials
107 trialsNCT05381753 2026-02-11
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
CStone Pharmaceuticals
Completed
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT03260894 2025-07-29
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT02231749 2025-06-26
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT02401815 2025-02-14
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Cogent Biosciences, Inc.
Phase 1/2 Completed
NCT00700258 2024-09-23
STAR-TOR
Pfizer
Completed
NCT05745142 2024-08-05
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
Pfizer
Completed
NCT04669366 2024-07-19
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
Pfizer
Completed
NCT02282059 2024-06-20
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Pfizer
Completed
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02264665 2023-11-13
OPALINE
Pfizer
Completed
NCT00716625 2023-05-03
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
Pfizer
Completed
NCT04175262 2023-05-03
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Pfizer
Completed
NCT05800106 2023-04-10
A Bioequivalence Study of Sunitinib Malate Capsules.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT00716820 2023-04-06
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
Pfizer
Completed
NCT04033991 2023-04-06
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Pfizer
Completed
NCT04076787 2023-04-06
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Pfizer
Completed
NCT02420821 2023-01-30
IMmotion151
Hoffmann-La Roche
Phase 3 Completed
NCT02432846 2022-08-22
MERECA
Mendus
Phase 2 Completed
NCT04115189 2022-05-10
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)
Pfizer
Completed
NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
NCT01024920 2021-07-19
Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
Boehringer Ingelheim
Phase 2 Completed
NCT01694277 2020-12-08
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
AB Science
Phase 3 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01984242 2019-12-23
IMmotion150
Hoffmann-La Roche
Phase 2 Completed
NCT00709995 2019-09-30
A Study for Participants With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT01525550 2019-07-30
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 4 Completed
NCT00428220 2019-06-27
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
Phase NA Completed
NCT01396148 2019-03-27
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed
NCT01258348 2019-01-10
A Phase 1b Trial in Patients With Renal Cell Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01506336 2018-12-11
Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
AB Science
Phase 2 Completed
NCT00599313 2018-10-25
Phase II Sunitinib Prog Met AIPC
US Oncology Research
Phase 2 Completed
NCT00864721 2018-10-16
Sunitinib Non Small Cell Lung Cancer Patients Over 70
US Oncology Research
Phase 2 Completed
NCT00375674 2018-09-21
S-TRAC
Pfizer
Phase 3 Completed
NCT01829841 2018-05-03
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01265901 2017-10-12
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Immatics Biotechnologies GmbH
Phase 3 Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed
NCT00617253 2017-03-01
Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
Novo Nordisk A/S
Phase 2 Completed
NCT00861419 2017-02-08
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
Amgen
Phase 1 Completed
NCT00444795 2017-02-01
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
Pfizer
Completed
NCT00903175 2016-11-08
RECORD-3
Novartis
Phase 2 Completed
NCT00821327 2016-10-25
Gemzar, Cisp, Sunitinib Urothelial Ca
US Oncology Research
Phase 2 Completed
NCT00705874 2016-07-21
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Progen Pharmaceuticals
Phase 1 Completed
NCT00793871 2015-11-20
GIST
Pfizer
Phase 4 Completed
NCT00599924 2015-07-15
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT01827254 2015-04-30
RESUME
Pfizer
Completed